 Immunomedics NASDAQ:IMMUs stock had its buy rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday, TipRanks reports. They currently have a 56.00 target price on the biopharmaceutical companys stock. HC Wainwrights price target suggests a potential upside of 40.11 from the companys previous close. A number of ... 